Moraga, Calif. August 4, 2015—Trigemina, Inc., a biopharmaceutical company focused on the discovery and development of non-narcotic, nasally delivered, analgesic drug products, announced today that the company has appointed Shashidhar “Shashi” Kori, M.D., to the position of chief medical officer. Dr. Kori brings over 30 years of clinical development experience to Trigemina, much of which has been focused in the neuroscience and headache space.
“We are thrilled to add Dr. Kori to our clinical team given his vast experience managing clinical development at leading biotech companies and more specifically in the headache space,” stated Charles Yeomans, president and chief executive officer of Trigemina. “Shashi’s experience in clinical trial design and product development will be key as we continue to advance our lead product, TI-114, toward a pivotal trial for migraine headaches.”
“The human clinical data that Trigemina has produced to date with its intranasal oxytocin product for migraine headaches have been very promising, and I am thrilled to be a part of the team that will see this product through late-stage clinical trials,” stated Dr. Kori. “The strong interest in Trigemina’s migraine drug candidate that is being shown by key opinion leaders in the headache and pain space is inspiring, and I look forward to teaming up with internal and external thought leaders to advance these products toward commercialization.”
Dr. Kori has more than 30 years of research and drug development experience in neurosciences. Before joining Trigemina, he served as chief medical officer at Autonomic Technologies, Inc. (ATI), where he was responsible for clinical research, clinical outcomes and regulatory submissions. He oversaw development and execution of all clinical research, including ATI’s clinical trials in the United States and in Europe. Prior to Joining ATI, he was vice president of clinical development and medical affairs at Allergan. Prior to Allergan, Dr. Kori was vice president of clinical development and medical affairs at MAP Pharmaceuticals, where he built the Medical Affairs department from the ground up. Prior to his time at MAP, he was senior director of clinical development at GlaxoSmithKline (GSK). In this role, Dr. Kori oversaw the design and execution of clinical studies and coordinated responses to FDA for migraine and pain products in development. Prior to GSK, Dr. Kori spent 24 years in academic medicine at major U.S. medical centers and universities (Sloan Kettering Cancer Center, Case Western Reserve University, Moffitt Cancer Center and Duke University) providing him with extensive experience in clinical patient care. Dr. Kori received his medical degree from Kasturba Medical College in Mangalore, India. He completed residencies in Internal Medicine at the VA Medical Center in Brooklyn, NY, and Neurology at St. Vincent’s Hospital and Medical Center in New York. He served fellowships in Neuro-oncology, Neuroimmunology and Immunobiology, and Cancer Pain at Memorial Sloan-Kettering Cancer Center, NY.
Trigemina (pronounced Tri-jem’-in-uh) is a privately owned, clinical stage company focused on the discovery and development of non-narcotic, nasally delivered, analgesic drug products. Trigemina’s lead product candidate, TI-114, is a patented new drug candidate that includes oxytocin. TI-114 has shown promising results for use as a safe and effective therapy for most forms of chronic or subacute head pain. Further information is available on the Company’s website: www.trigemina.com.
For Further Information Contact:
President and CEO, Trigemina
Cook Williams Communications, Inc.